Literature DB >> 18081642

Review article: The endoscopic treatment of gastro-oesophageal reflux disease.

M P Schwartz1, A J P M Smout.   

Abstract

BACKGROUND: Over the last 10 years a number of endoscopic procedures for treating gastro-oesophageal reflux disease (GORD) have been developed (suturing, injections, implants and radiofrequency ablation), thus obviating the need for long-term proton pump inhibitors (PPI) and the potential morbidity of laparoscopic fundoplication. AIM: To present an update of the literature studying the clinical efficacy of endoscopic antireflux procedures, and to discuss further developments.
METHODS: A PubMed search was performed for endoscopic suturing, antireflux treatment, endoscopic gastroplication, polymer injection, radiofrequency ablation of GORD. Own recent research was compared with existing data. Information concerning GORD endotherapy were gathered.
RESULTS: Uncontrolled studies have reported promising clinical results on the short to intermediate term for most endoscopic GORD procedures, but the placebo effect remained unknown. It is, therefore, commendable that the three main procedures (Endocinch, Stretta and Enteryx) have now all been tested against a sham procedure. Although all three techniques were able to improve symptoms, quality of life and PPI use, oesophageal acid reduction was unremarkable. Endocinch and Stretta are safe outpatient procedures. Concerns about the durability of Endocinch have risen. Polymer injection (Enteryx) and gel prosthesis implantation (Gatekeeper) were recalled for severe complications and lack of efficacy, respectively.
CONCLUSIONS: Endotherapy has shown the potential to treat (uncomplicated) GORD. However, some early procedures have failed or proven unsafe. Further developments and studies are necessary to determine what modifications to these techniques are required to produce optimal efficacy and durability. Until then, widespread clinical use of endotherapy for GORD should probably be avoided.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18081642     DOI: 10.1111/j.1365-2036.2007.03473.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

1.  Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy.

Authors:  Tiberiu Hershcovici; Ronnie Fass
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Endoscopic augmentation of the esophagogastric junction with polymethylmethacrylate: durability, safety, and efficacy after 6 months in mini-pigs.

Authors:  Fernando Fornari; Carmen P F Freitag; Marcos E S Duarte; Cleber R P Kruel; Paulo R O Thomé; Paulo R S Sanches; Luise Meurer; Carlos T Z Cerski; Cesar Liberato Petzhold; Sidia M Callegari-Jacques; Sérgio G S Barros
Journal:  Surg Endosc       Date:  2009-02-28       Impact factor: 4.584

3.  The Proton Pump Inhibitor Non-Responder: A Clinical Conundrum.

Authors:  Zilla H Hussain; Emily E Henderson; Carla Maradey-Romerao; Nina George; Ronnie Fass; Brian E Lacy
Journal:  Clin Transl Gastroenterol       Date:  2015-08-13       Impact factor: 4.488

4.  Antireflux endoluminal therapies: past and present.

Authors:  Kuo Chao Yew; Seng-Kee Chuah
Journal:  Gastroenterol Res Pract       Date:  2013-07-09       Impact factor: 2.260

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.